24/7 Market News Snapshot 23 January, 2025 – Vigil Neuroscience, Inc. Common Stock (NASDAQ:VIGL)

January 23, 2025

DENVER, Colo., 23 January, 2025 (247marketnews.com) – (NASDAQ:VIGL) are discussed in this article.
Vigil Neuroscience, Inc. has recently demonstrated notable market activity as its stock opened at $2.29 but subsequently experienced a decline, currently trading at $2.235. This marks a significant decrease of 10.10% from the prior closing price of $2.030, coupled with an impressive volume surge, reaching 19.91 million shares. Such fluctuations indicate heightened investor interest, although the prevailing bearish trend may reflect profit-taking or unfavorable market conditions. Analysts are closely monitoring key support levels around $2.00 and resistance at $2.29, which will be essential for future price direction.

In parallel, Vigil Neuroscience has released promising findings from its Phase 1 clinical trial of VG-3927, an innovative oral therapy for Alzheimer’s disease. The trial results highlighted VG-3927’s robust safety, tolerability, and pharmacodynamic profile, showcasing its potential as a next-generation treatment. Dr. Ivana Magovčević-Liebisch, President and CEO, emphasized the significance of these results, noting that the data reinforce Vigil’s commitment to developing VG-3927 as a viable therapy for Alzheimer’s.

The Phase 1 trial, which included 115 participants, revealed a favorable safety profile with no serious adverse events. A critical finding was the reduction of sTREM2 levels in cerebrospinal fluid, indicating successful target engagement. Vigil aims to initiate a Phase 2 trial in the third quarter of 2025, targeting a 25mg once-daily dose that fully harnesses the drug’s pharmacological effects.

Dr. Petra Kaufmann, Chief Medical Officer, highlighted the neuroprotective potential of VG-3927 in addressing the unmet needs within Alzheimer’s research. Vigil is set to present additional data at the upcoming AD/PD™ 2025 International Conference, further solidifying its commitment to advancing therapeutic options for neurodegenerative diseases.

Related news for (VIGL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.